Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.

In English

Författare

Summary, in English

Introduction: Rivaroxaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary but the dose dependent effects on common reagents and assay procedures are largely unknown. Objectives: To investigate the effect of rivaroxaban on commonly used coagulation assays. Material and Methods: Rivaroxaban was added to plasma from healthy subjects in the concentration range 0 -1000 μg/L and analyzed using different reagents for activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin, fibrinogen and activated protein C (APC) resistance assays. Results: At an expected peak concentration of rivaroxaban in clinical use, the APTTs were almost invariably prolonged but at lower concentrations the effect was weak. The concentration needed to double the APTT varied between 389 ±106 μg/L to 617 ±149 μg/L for different reagents. The PT assays showed a marked degree of difference. In general, the Quick PT type assays were more sensitive compared to the Owren type PT assays. The results from antithrombin assays were dependent on the type of reagent with the Xa-based assay being sensitive for rivaroxaban with an estimated increase of 0.09 IU/mL per 100 μg/L rivaroxaban. There were only minor effects on fibrinogen assays based on thrombin reagents. The APTT-based assay for APC resistance is affected in a dose dependent manner whereas an assay based on the activation of coagulation at the prothrombinase level was unaffected. Conclusions: Different assays, and even different reagents within an assay group, display variable effects by therapeutic concentrations of rivaroxaban.

Publiceringsår

2011

Språk

Engelska

Sidor

133-139

Publikation/Tidskrift/Serie

Journal of Thrombosis and Haemostasis

Volym

9

Dokumenttyp

Artikel i tidskrift

Förlag

Wiley-Blackwell

Ämne

  • Cardiac and Cardiovascular Systems

Status

Published

Forskningsgrupp

  • Clinical Chemistry, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 1538-7933